ARIAD Pharma (ARIA) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Join SI Premium – FREE
ARIAD Pharma (NASDAQ: ARIA) reported Q3 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $34.3 million versus the consensus estimate of $42.93 million.
ARIAD Pharma reaffirmed FY2016 guidance.
For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AptarGroup (ATR) Tops Q3 EPS by 5c
- FTI Consulting (FCN) Tops Q3 EPS by 110c; offers guidance
- Portland General Electric (POR) Misses Q3 EPS by 13c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
